89 related articles for article (PubMed ID: 15133498)
1. An activated mTOR mutant supports growth factor-independent, nutrient-dependent cell survival.
Edinger AL; Thompson CB
Oncogene; 2004 Jul; 23(33):5654-63. PubMed ID: 15133498
[TBL] [Abstract][Full Text] [Related]
2. Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate.
Vanderweele DJ; Rudin CM
Mol Cancer Res; 2005 Nov; 3(11):635-44. PubMed ID: 16317089
[TBL] [Abstract][Full Text] [Related]
3. Growth factors regulate cell survival by controlling nutrient transporter expression.
Edinger AL
Biochem Soc Trans; 2005 Feb; 33(Pt 1):225-7. PubMed ID: 15667313
[TBL] [Abstract][Full Text] [Related]
4. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53.
Mungamuri SK; Yang X; Thor AD; Somasundaram K
Cancer Res; 2006 May; 66(9):4715-24. PubMed ID: 16651424
[TBL] [Abstract][Full Text] [Related]
5. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
[TBL] [Abstract][Full Text] [Related]
6. Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt.
Asnaghi L; Calastretti A; Bevilacqua A; D'Agnano I; Gatti G; Canti G; Delia D; Capaccioli S; Nicolin A
Oncogene; 2004 Jul; 23(34):5781-91. PubMed ID: 15208671
[TBL] [Abstract][Full Text] [Related]
7. Mechanical stimuli and nutrients regulate rapamycin-sensitive signaling through distinct mechanisms in skeletal muscle.
Hornberger TA; Chien S
J Cell Biochem; 2006 Apr; 97(6):1207-16. PubMed ID: 16315321
[TBL] [Abstract][Full Text] [Related]
8. Akt activation protects pancreatic beta cells from AMPK-mediated death through stimulation of mTOR.
Cai Y; Wang Q; Ling Z; Pipeleers D; McDermott P; Pende M; Heimberg H; Van de Casteele M
Biochem Pharmacol; 2008 May; 75(10):1981-93. PubMed ID: 18377870
[TBL] [Abstract][Full Text] [Related]
9. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
10. IGF-1 protects oligodendrocyte progenitors against TNFalpha-induced damage by activation of PI3K/Akt and interruption of the mitochondrial apoptotic pathway.
Pang Y; Zheng B; Fan LW; Rhodes PG; Cai Z
Glia; 2007 Aug; 55(11):1099-107. PubMed ID: 17577243
[TBL] [Abstract][Full Text] [Related]
11. Rheb activation of mTOR and S6K1 signaling.
Hanrahan J; Blenis J
Methods Enzymol; 2006; 407():542-55. PubMed ID: 16757352
[TBL] [Abstract][Full Text] [Related]
12. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.
Bibollet-Bahena O; Almazan G
J Neurochem; 2009 Jun; 109(5):1440-51. PubMed ID: 19453943
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin inhibits Akt-mediated oncogenic transformation and tumor growth.
Liu X; Powlas J; Shi Y; Oleksijew AX; Shoemaker AR; De Jong R; Oltersdorf T; Giranda VL; Luo Y
Anticancer Res; 2004; 24(5A):2697-704. PubMed ID: 15517874
[TBL] [Abstract][Full Text] [Related]
14. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.
Xu Y; Chen SY; Ross KN; Balk SP
Cancer Res; 2006 Aug; 66(15):7783-92. PubMed ID: 16885382
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity.
Tirado OM; Mateo-Lozano S; Notario V
Oncogene; 2005 May; 24(20):3348-57. PubMed ID: 15782132
[TBL] [Abstract][Full Text] [Related]
16. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
Klos KS; Wyszomierski SL; Sun M; Tan M; Zhou X; Li P; Yang W; Yin G; Hittelman WN; Yu D
Cancer Res; 2006 Feb; 66(4):2028-37. PubMed ID: 16489002
[TBL] [Abstract][Full Text] [Related]
17. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
18. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.
Yan H; Frost P; Shi Y; Hoang B; Sharma S; Fisher M; Gera J; Lichtenstein A
Cancer Res; 2006 Feb; 66(4):2305-13. PubMed ID: 16489035
[TBL] [Abstract][Full Text] [Related]
19. The mammalian target of rapamycin-signaling pathway in regulating metabolism and growth.
Yang X; Yang C; Farberman A; Rideout TC; de Lange CF; France J; Fan MZ
J Anim Sci; 2008 Apr; 86(14 Suppl):E36-50. PubMed ID: 17998426
[TBL] [Abstract][Full Text] [Related]
20. Controlling cell growth and survival through regulated nutrient transporter expression.
Edinger AL
Biochem J; 2007 Aug; 406(1):1-12. PubMed ID: 17645414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
